Avtal | $24,000,000 | (Mar 20, 2026)
games2gether | $5,202,945 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
oncgnostics GmbH
Germany
- Jena, Thüringen
- 11/09/2023
- Unknown
- Undisclosed Amount
oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
- Industry Biotechnology Research
- Website https://www.oncgnostics.com/
- LinkedIn https://www.linkedin.com/company/oncgnostics/about/
Related People
Martina SchmitzFounder
Germany -
Jena, Thuringia
oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
First product is our CE IVD marked test "GynTect", a 2nd-line test for reliably detecting cervical cancer.
A short comic (german) explains what GynTect is doing.
On the Seedmatch-platform, there are a lot of insides on our company (german) and two nice videos about our company.
2016: https://www.seedmatch.de/startups/oncgnostics-2
2017: https://www.seedmatch.de/startups/oncgnostics
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
Ezra AI Labs | $3,200,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Health Universe | $6,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)